Select Page
Optimizing Nursing Care for Patients With Ovarian Cancer: What do Nurses Need to Know About PARP Inhibitors?

This webcast is no longer certified for credit

Optimizing Nursing Care for Patients With Ovarian Cancer: What do Nurses Need to Know About PARP Inhibitors?

An Independent Satellite Symposium held during the Oncology Nursing Society‘s (ONS) 42nd Annual Congress

OVERVIEW

Given the recent and imminent approval of novel PARP inhibitors and the associated volume of emerging data, nurses treating patients with ovarian cancer need expert guidance to evaluate emerging scientific and clinical data, use existing PARP inhibitors safely and effectively, and plan strategies to appropriately integrate new ones into practice when they become available, in consideration of patient needs and preferences. During the webcast, this expert panel will discuss diagnostic criteria, including molecular testing of patients, for determining eligibility for PARP inhibitors and identifying which agent will have the most benefit for your patients.

 

TARGET AUDIENCE

The target audience for this activity is oncology nurses and other clinicians who treat patients with ovarian cancer.

 

LEARNING OBJECTIVES

After completing this activity, participants should be better able to:

  • Explain how genetic testing is utilized appropriately in patients with ovarian cancer
  • Interpret the clinical significance of emerging safety and efficacy data for available and novel PARP inhibitors
  • Plan strategies to prevent and manage side effects of PARP inhibition
  • Identify when and how to dose modify PARP inhibitors according to best practices

 

PRESENTATION TOPICS

Slides are available to download throughout the webcast

Diagnostic Criteria and Aligning Currently Available and Emerging PARP Inhibitors to Appropriate Patients
Shannon N. Westin, MD, MPH, FACOG

Preventing and Managing Adverse Events of PARP Inhibitors
Paula J. Anastasia, RN, MN, AOCN

Effects of Dose Modification of PARP Inhibitors
Chrisann A. Winslow, RN, MSN-R, AOCN

Case Studies Regarding Key Clinical Challenges

Panel Discussion and Q&A

 

METHOD OF PARTICIPATION

There are no fees for viewing this activity. The estimated viewing time is 75 minutes.

 

CONTINUING EDUCATION

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

The UNMC CON CNE has been awarded Accreditation with Distinction, the highest recognition awarded by the American Nurses Credentialing Center’s Accreditation Program. This distinction is valid through 2020.

This activity was planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation (ANCC) through the joint providership of the University of Nebraska Medical Center College of Nursing Continuing Nursing Education (UNMC CON CNE) (provider) and Bio Ascend.

 

SUPPORT

Educational grant support provided by Clovis Oncology.

 

HARDWARE/SOFTWARE REQUIREMENTS

Below are the requirements to access online activities:

  • Supported operating systems: Windows 7, Windows 8, Windows 10, iPad iOS 9+, and Mac OS X
  • Supported Browsers: PC – Chrome, Edge, Firefox, and Internet Explorer 11. Mac – Chrome, Firefox, and Safari. iPad – Safari
  • This activity is best experienced with a high-speed Internet connection, such as T1, cable, DSL, etc.
  • Javascript must be enabled to view this activity. Need help? Go to – www.enable-javascript.com

 

CHAIR

Paula J. Anastasia, RN, MN, AOCN
Cedars-Sinai Medical Center
Los Angeles, California

FACULTY

Shannon N. Westin, MD, MPH, FACOG
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Chrisann A. Winslow, RN, MSN-R, AOCN
Washington University School of Medicine
St. Louis, Missouri

DISCLOSURE INFORMATION

Paula J. Anastasia, RN, MN, AOCN

Honoraria: Clovis Oncology, Genentech

Speakers’ Bureau: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

 

Shannon N. Westin, MD, MPH, FACOG

Consultant Fees: AstraZeneca, Casdin Capital

Speakers’ Bureau: Medscape

Scientific Advisory Board: ASCO Leadership Development, Clovis Oncology, Genentech, Medivation, Inc., Aspira Labs, A Vermillion Company

Grants/Research Support: AstraZeneca, Critical Outcomes Technology, Inc. (COTI), Novartis

 

Chrisann A. Winslow, RN, MSN-R, AOCN

Honoraria: Clovis Oncology

 

PROVIDER & DISCLOSURE STATEMENTS

All planners and faculty participating in continuing education activities provided by the University of Nebraska Medical Center College of Nursing Continuing Nursing Education are expected to disclose to the audience any support or relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation. The planners and faculty have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

The following planning committee members stated they have no conflicts to disclose:

Heidi Keeler, PhD, RN
Renee Paulin, MSN, RN, CWOCN
Dru Dace, PhD

DISCLOSURE OF OFF-LABEL USE

No product purposes, other than those approved by the FDA, will be discussed.

NON-ENDORSEMENT OF PRODUCTS

Accredited status as a provider of continuing nursing education refers only to the University of Nebraska Medical Center College of Nursing Continuing Nursing Education continuing education activities, and does not imply UNMC or American Nurses Credentialing Center’s Commission on Accreditation endorsement of any commercial supporters.

This activity is jointly provided by the University of Nebraska Medical Center College of Nursing Continuing Nursing Education and Bio Ascend

Copyright © 2018 Bio Ascend LLC

Bio Ascend LLC
980 N Michigan Avenue, Suite 1400
Chicago, IL 60611
(p)773-304-5019
(f)312-277-6893 | info@bioascend.com | cme@bioascend.com | program@bioascend.com

Bio Ascend LLC observes pharmaceutical industry compliance and regulatory guidelines.